Hasil Pencarian (2)
small molecule | CAS: 1374248-81-3
Atogepant is an oral antagonist of calcitonin gene-related peptide (CGRP) receptors indicated for the prevention of episodic migraine headaches. It was developed by AbbVie and received FDA approval under the brand name Qulipta in September 2021.[L38814] While…
Kategori:
AnalgesicsAntimigraine PreparationsBCRP/ABCG2 Substrates
+14
Target Protein:
Calcitonin gene-related peptide type 1 receptor
Waktu ParuhThe elimination hal…
Vol. DistribusiThe mean apparent v…
KlirensThe mean apparent o…
Genetik
-
small molecule | CAS: 1289023-67-1
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals.[L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in A…
Kategori:
AnalgesicsAntimigraine PreparationsBCRP/ABCG2 Substrates
+19
Target Protein:
Calcitonin gene-related peptide type 1 receptor
Waktu ParuhThe elimination hal…
Vol. DistribusiAt steady state, th…
Klirens-
Genetik
-